Caplin Point Laboratories Limited (CAPLIPOINT) AI Stock Analysis

• Market Cap: ₹123.25B
• Dividend Yield: 0.31%
• Average Volume (3M): 3.75K
• Price to Earnings (P/E): 21.3
• Beta (1Y): 1.27
• Revenue Growth: 11.41%
• EPS Growth: 19.22%
• Country: IN
• Employees: 3,406
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 21.80
• Shares Outstanding: 76,011,696
• 10 Day Avg. Volume: 2,866
• 30 Day Avg. Volume: 3,752
• PEG Ratio: 1.63
• Price to Book (P/B): 5.30
• Price to Sales (P/S): 7.78
• P/FCF Ratio: 62.69
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 85.1
• Revenue Forecast (FY): ₹22.39B

• Rating: 69 Neutral
• Price Target: ₹1,776.00 ▼(-3.79% Downside)
• Action: Downgraded Date: 09/27/25
• Date: Action: Downgraded 09/27/25

Caplin Point Laboratories' strong financial performance is the primary driver of its stock score, reflecting robust revenue growth and solid profitability. However, technical indicators suggest a bearish trend, and the valuation appears moderately high, which tempers the overall score.

Positive Factors

Revenue & Profitability

Consistent multi-year revenue growth and robust margins indicate durable demand and operational efficiency. Sustained profitability supports reinvestment into differentiated formulations, funds regulatory filings, and underpins stable cash generation that can finance growth without excessive external funding.

Balance Sheet Strength

Low leverage and a strong equity position provide financial flexibility for capex, capacity expansion and navigating regulatory timelines. A conservative balance sheet reduces refinancing risk and preserves ability to fund tenders, launches or M&A without destabilizing liquidity.

Cash Generation

Stable operating and free cash flow supports ongoing product registrations, maintenance of injectable/ophthalmic manufacturing, and working capital for international distribution. Strong cash conversion sustains investment and deleveraging options over the medium term.

Negative Factors

Tender-driven Revenue Volatility

Reliance on tender and contract awards creates lumpy, price-competitive revenue streams that can fluctuate materially by geography and period. Winning cycles and pricing pressure from tenders can compress margins and make near-term top-line visibility and predictability weaker for several months.

Distribution & Partner Dependence

Heavy use of third-party distributors limits direct control over market access, pricing and inventory flow. This can dilute margins, slow commercial response to demand shifts, and create counterparty and execution risk in key international markets over a multi-month horizon.

Regulatory Approval Dependence

Growth depends on timely regulatory approvals and product registrations; delays or rejections can defer revenue realization. Regulatory cycles and compliance demands add execution risk and capex needs, making product launches and international scaling contingent on external review timelines.

Caplin Point Laboratories Limited Business Overview & Revenue Model

Company Description

Caplin Point Laboratories Limited develops, produces, markets, and exports generic pharmaceutical formulations and branded products in India. The company provides liquid and lyophilized injections, ophthalmic products, tablets, liquid orals, capsules, softgel capsules, suppositories and ovules, powder for injection, dry syrups, topicals, inhalers, IV infusions, lyophilized products, branded products, dermo cosmetics, and other products. It also operates QueTenX, an e-commerce website. The company was incorporated in 1990 and is headquartered in Chennai, India.

How the Company Makes Money

Caplin Point makes money primarily by selling generic pharmaceutical products, with revenue generated from (1) international sales of finished-dosage formulations to distributors, hospitals, pharmacies, and institutional buyers in its key overseas markets; and (2) contract-based and tender-driven procurement channels where product volumes are awarded through competitive bids, particularly for certain geographies and product categories. A meaningful part of its earning model is built around producing differentiated formulations (notably injectables and ophthalmics), which can support relatively stronger pricing and demand stability versus commoditized oral solids when supply is constrained or product complexity is higher. The company also earns by leveraging its manufacturing capabilities and regulatory approvals to launch products across multiple markets, monetizing its product registrations through ongoing sales once approvals are in place. Specific information on the breakdown of revenue by product line, customer segment, or named partnerships is null.

Caplin Point Laboratories Limited Financial Statement Overview

Summary

Caplin Point Laboratories exhibits strong financial health with impressive revenue growth, efficient operations, and solid profitability. The balance sheet is robust with low leverage and high equity, while cash flow generation is ample and sustainable.

Income Statement

Caplin Point Laboratories has demonstrated strong revenue growth, with a significant increase in total revenue over the past five years. The gross profit margin is robust, indicating efficient cost management. Additionally, the EBIT and EBITDA margins highlight strong operational performance, while the net profit margin reflects effective bottom-line management.

Balance Sheet

The company's balance sheet is solid, featuring a low debt-to-equity ratio which suggests prudent financial leverage. The equity ratio is high, showcasing a strong equity position relative to total assets. Return on equity has shown positive trends, reflecting good profitability on shareholders' investments.

Cash Flow

Caplin Point Laboratories has a healthy cash flow, with consistent growth in free cash flow. The operating cash flow to net income ratio indicates strong cash generation relative to net income, supporting business sustainability. The free cash flow to net income ratio is solid, ensuring ample cash availability for reinvestment or debt reduction.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	20.42B	19.40B	16.96B	14.68B	12.71B	10.62B
Gross Profit	11.43B	11.38B	9.40B	7.89B	6.99B	5.82B
EBITDA	7.29B	6.49B	5.51B	4.40B	3.94B	3.28B
Net Income	5.89B	5.36B	4.57B	3.76B	3.00B	2.42B
Balance Sheet
Total Assets	35.04B	32.09B	26.98B	21.91B	17.36B	13.64B
Cash, Cash Equivalents and Short-Term Investments	10.17B	9.03B	7.88B	6.50B	5.13B	4.46B
Total Debt	85.00M	50.20M	19.70M	54.80M	21.30M	183.92M
Total Liabilities	3.05B	3.22B	3.51B	2.84B	2.26B	1.60B
Stockholders Equity	31.59B	28.50B	23.16B	18.80B	14.84B	11.86B
Cash Flow
Free Cash Flow	1.60B	2.41B	1.73B	779.00M	2.46B	1.95B
Operating Cash Flow	2.54B	4.32B	3.18B	2.72B	3.37B	2.66B
Investing Cash Flow	-2.99B	-3.35B	-3.20B	-2.18B	-3.77B	-294.40M
Financing Cash Flow	-460.10M	-383.20M	-380.70M	-281.70M	-407.10M	-239.78M

Caplin Point Laboratories Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1845.95
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:CAPLIPOINT, the sentiment is Negative. The current price of 1845.95 is above the 20-day moving average (MA) of 1682.39, above the 50-day MA of 1746.95, and below the 200-day MA of 1969.19, indicating a bearish trend. The MACD of -30.33 indicates Negative momentum. The RSI at 38.79 is Neutral, neither overbought nor oversold. The STOCH value of 23.94 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:CAPLIPOINT.

Caplin Point Laboratories Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NATCOPHARM	76 Outperform	₹167.83B	26.69	―	0.57%	-3.79%	-20.88%
GRANULES	73 Outperform	₹141.31B	24.17	―	0.24%	8.14%	5.18%
CAPLIPOINT	69 Neutral	₹123.25B	21.31	―	0.31%	11.41%	19.22%
APLLTD	60 Neutral	₹128.99B	31.27	―	1.28%	11.42%	-1.91%
NEULANDLAB	60 Neutral	₹155.16B	119.97	―	0.08%	0.34%	-14.13%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Caplin Point Laboratories Limited Corporate Events

Caplin Point Buys $473 Million Portfolio of US-Approved Injectable and Ophthalmic ANDAs

Caplin Point Laboratories, through its subsidiaries Caplin Steriles and Caplin One Labs, has acquired 10 approved Abbreviated New Drug Applications (ANDAs) for injectable and ophthalmic products from a leading multinational generic manufacturer, covering an addressable market of $473.2 million for the year ended August 2025. The deal strengthens Caplin’s U.S. portfolio—now including select oncology injectables to be commercialized from its new oncology facility in Kakkalur—and supports its strategy to deepen presence in the U.S. while progressively rolling out these products to key non-U.S. markets such as Mexico, Canada, the European Union and Brazil, reinforcing the company’s positioning as a growing global player in sterile and oncology generics.